Physician profile
Joy T Vanterpool
NPI 1710966684
$11,629.71
in general payments reported to CMS, 2019-2025
42 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $2,001 · 2021: $2,654 · 2022: $1,799 · 2023: $1,466 · 2024: $1,330 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,490.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,219.91 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Pfizer INC. | $982.95 | 2019-2025 | |
| Lilly USA, LLC | $934.19 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $932.45 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $861.26 | 2019-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $826.00 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $518.80 | 2021-2024 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $439.84 | 2019-2022 | |
| Mylan Specialty L.P. | $420.24 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $383.03 | 2020-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $335.23 | 2022-2025 | |
| Exact Sciences Corporation | $252.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $228.97 | 2020-2021 | |
| Amarin Pharma, INC. | $228.26 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Vanterpool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.